Back To Schedule
Saturday, June 19 • 12:00pm - 1:00pm
#531 OD: Antibody-Drug Conjugate Drug Development: From Novel Technology to New Patient Therapy

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Session
Level: Intermediate

In this session, the expert speakers will describe and discuss the key learnings from this cutting-edge and arguably intriguing topic and promote open thoughts on how to innovate next-generation of ADC development and identify new opportunities to broaden ADC applications to deliver new therapies to help fulfill unmet medical needs.

Learning Objectives

Illustrate up-to-date ADCs drug development landscape along with therapeutic applications and opportunities; Describe scientific rationales for Antibody-Drug Conjugate (ADC) drug design and novel technological platforms; Discuss case studies of novel ADCs development from bench to clinical and from clinical to successful launch; Discuss strategic and operational considerations unique to ADC including key challenges and translational needs for ADC drugs from preclinical into clinical.


Angela Qu, MD, PhD


The Evolution of Antibody-Drug Conjugates in the Era of Precision Medicine Development
Angela Qu, MD, PhD

Bispecific ADC Technology Platforms and M1231: A Bispecific ADC Targeting EGFR and MUC1
Joern-Peter Halle, PhD

Before the DREAMM: Preclinical Findings Leading to Development of Belantamab Mafodotin
Joanna B. Opalinska, MD

avatar for Angela Qu

Angela Qu

Vice President, Translational Medicine, Parexel, United States
Dr. Qu is Vice President in Parexel Translational Medicine, leading therapeutic strategy development and implementation of genomics and biomarker clinical studies, provision of scientific guidance, and consulting on partnerships across therapeutic areas. She serves as a core member... Read More →
avatar for Joern-Peter Halle

Joern-Peter Halle

Senior Vice President, Global Head of Research, Merck KGaA, Germany
Peter is leading the global discovery and research organization at Merck and a member of the Healthcare Executive Committee. He oversees the discovery and development technology platforms and the research and translational activities across three focus areas of oncology, immune-oncology... Read More →
avatar for Joanna Opalinska

Joanna Opalinska

Senior Director, Oncology Clinical Development, GlaxoSmithKline, United States
Joanna Opalinska trained as clinical hematologist/oncologist in Poland and in Germany. Joanna developed further skills in basic and translational research in the area of normal and malignant hematopoiesis and modulation of gene expression by antisense technology at the University... Read More →

Saturday June 19, 2021 12:00pm - 1:00pm EDT
TBD Virtual Event Horsham, PA 19044
  06: PreClin Dev-EarlyPhaseCR, Session |   20: Early Access Content, Session